Summary of COVID-19 ratutrelvir studies

1. Dokukina et al., Traws Pharma Files Tivoxavir Marboxil Investigational New Drug (IND) Application for Influenza Therapy, and Provides Updated Results from the Ongoing Clinical Study of Ratutrelvir in PAXLOVID®-Eligible and Ineligible COVID-19 Patients

50 patient ratutrelvir early treatment RCT: 14% improved recovery (p=0.01).
Interim results showing improved time-to-sustained symptom alleviation and resolution with ratutrelvir.
Jan 2026, NCT07157007, https://www.trawspharma.com/press-release-single?id=traws-pharma-files-tivoxavir-marboxil-investigational-new-drug-ind-application-for-influenza-therapy-and-provides-updated-results-from-the-ongoing-clinical-study-of-ratutrelvir-in-paxlovid-r-eligible-and-ineligible-covid-19-patients, https://c19p.org/dokukina